Free Trial

CSL (CSLLY) Stock Forecast & Price Target

CSL logo
$71.68 +0.77 (+1.09%)
As of 04:00 PM Eastern

CSL - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
1
Buy
1

Based on 3 Wall Street analysts who have issued ratings for CSL in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a strong buy rating for CSLLY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CSLLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CSL and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CSLLY Analyst Ratings Over Time

TypeCurrent Forecast
10/16/24 to 10/16/25
1 Month Ago
9/16/24 to 9/16/25
3 Months Ago
7/18/24 to 7/18/25
1 Year Ago
10/17/23 to 10/16/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldModerate BuyStrong BuyStrong Buy

CSLLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSLLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CSL Stock vs. The Competition

TypeCSLMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.33
2.52
Consensus RatingHoldHoldModerate Buy
Predicted UpsideN/A1,036.68% Upside12.98% Upside
News Sentiment Rating
Positive News

See Recent CSLLY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/6/2025Canaccord Genuity Group
3 of 5 stars
 UpgradeHold
9/15/2025Zacks Research
0 of 5 stars
 DowngradeHoldStrong Sell
1/16/2025The Goldman Sachs Group
3 of 5 stars
D. Thillainathan
Not Rated
UpgradeStrong-Buy
8/13/2024Macquarie
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:52 PM ET.


Should I Buy CSL Stock? CSLLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 14, 2025. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com.

CSL
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CSL Limited:

  • The current stock price is around $67.75, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • CSL Limited has a strong presence in the biopharmaceutical market, with operations in multiple countries, enhancing its global reach and potential for revenue growth.
  • The company has been recognized for its innovative products, particularly in plasma therapies and gene therapies, which are in high demand and can lead to significant market share.
  • CSL Limited's diverse segments, including CSL Behring and CSL Seqirus, allow it to mitigate risks associated with market fluctuations in any single area.
  • Recent upgrades in stock ratings by analysts indicate positive sentiment and potential for future growth, suggesting that the market views CSL Limited favorably.

CSL
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CSL Limited for these reasons:

  • Recent downgrades from analysts, including a shift from a "hold" to a "strong sell" rating, may indicate underlying concerns about the company's performance.
  • CSL Limited's stock has experienced volatility, with a 12-month high of $101.44 and a low of $61.06, suggesting potential instability in its market value.
  • The company's debt-to-equity ratio of 0.50 indicates a moderate level of debt, which could pose risks if market conditions worsen or if interest rates rise.
  • Competition in the biopharmaceutical industry is intense, and CSL Limited may face challenges in maintaining its market position against emerging players.
  • Fluctuations in demand for its products, particularly in the context of global health crises, could impact revenue stability and growth prospects.

CSLLY Forecast - Frequently Asked Questions

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last year. There is currently 1 sell rating, 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CSLLY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CSLLY, but not buy additional shares or sell existing shares.

According to analysts, CSL's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, CSL's stock had 1 upgrade and 1 downgrade by analysts.

CSL has been rated by research analysts at Canaccord Genuity Group, and Zacks Research in the past 90 days.

Analysts like CSL more than other "medical" companies. The consensus rating score for CSL is 2.33 while the average consensus rating score for "medical" companies is 2.33. Learn more on how CSLLY compares to other companies.


This page (OTCMKTS:CSLLY) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners